← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Proteogenomics Research Instit/Sys/ Med
La Jolla, CA
$44,484,148
Total funding
23
Grants
Funding over time
peak $13.4M · FY2015–25$20M$15M$10M$5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,484,148 · 23
By mechanism
P01$26,763,351 · 14
R01$15,320,414 · 7
U01$2,400,383 · 2
Investigators at Proteogenomics Research Instit/Sys/ Med
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Precision Delivery and Imaging to Enhance Solid Tumor Therapy$2,788,878
P01 · FY2019 · CA
Novel Targeted Therapies for Pulmonary Fibrosis$2,783,129
P01 · FY2015 · HL
Novel Targeted Therapies for Pulmonary Fibrosis$2,698,274
P01 · FY2016 · HL
Novel Targeted Therapies for Pulmonary Fibrosis$2,698,059
P01 · FY2017 · HL
Novel Targeted Therapies for Pulmonary Fibrosis$2,697,831
P01 · FY2018 · HL
Novel Targeted Therapies for Pulmonary Fibrosis$2,697,594
P01 · FY2019 · HL
Precision Delivery and Imaging to Enhance Solid Tumor Therapy$2,678,066
P01 · FY2021 · CA
Precision Delivery and Imaging to Enhance Solid Tumor Therapy$2,667,097
P01 · FY2020 · CA
Precision Delivery and Imaging to Enhance Solid Tumor Therapy$2,534,428
P01 · FY2022 · CA
Precision Delivery and Imaging to Enhance Solid Tumor Therapy$2,519,995
P01 · FY2023 · CA
Clinical Trials for Imaging and Therapy$1,034,972
P01 · FY2023 · CA
Bispecific immunotherapeutic delivery system for lung diseases$924,314
R01 · FY2025 · HL
Bispecific immunotherapeutic delivery system for lung diseases$924,314
R01 · FY2023 · HL
Bispecific immunotherapeutic delivery system for lung diseases$905,828
R01 · FY2024 · HL
Clinical Trials for Imaging and Therapy$864,904
P01 · FY2022 · CA
Localizing Therapeutics to Target Lung Myofibroblasts and Reverse Fibrosis$805,845
R01 · FY2024 · HL
Localizing Therapeutics to Target Lung Myofibroblasts and Reverse Fibrosis$782,151
R01 · FY2025 · HL
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$749,235
R01 · FY2019 · CA
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$735,974
R01 · FY2020 · CA
Endothelial Cell-Targeted Amatoxin Conjugates for Effective Therapy of Breast Cancer$722,712
R01 · FY2021 · CA